MedTrace Logo

Treatment of Intrauterine Growth Restriction With Low Molecular Heparin.

NCT03324139 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-04-22

No results posted yet for this study

Summary

TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN.

Conditions

  • Intrauterine Growth Restriction

Interventions

DRUG

Low molecular weight heparin

Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).

DRUG

Placebos

Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).

Sponsors & Collaborators

  • Servicio de Asesoría a la Investigación y Logística SL

    collaborator OTHER

  • Fundació Sant Joan de Déu

    lead OTHER

Principal Investigators

  • Edurne Mazarico · Hospital Sant Joan de Deu

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-25
Primary Completion
2022-04-30
Completion
2023-02-19

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03324139 on ClinicalTrials.gov